GlassScriptPhysician profile
David Yin
NPI 1992151153
$3,920.58
in general payments reported to CMS, 2019-2025
45 companies · $1,427 in 2025
The $1,427 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2020: $14.75 · 2022: $281 · 2023: $729 · 2024: $1,244 · 2025: $1,427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,121 · Education: $279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,121.24 |
| Education | $278.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $408.40 | 2023-2025 | |
| Glaxosmithkline, LLC. | $359.55 | 2022-2025 | Ojjaara, Zejula, Jemperli |
| Incyte Corporation | $316.48 | 2022-2025 | Jakafi, Monjuvi |
| E.R. Squibb & Sons, L.L.C. | $269.15 | 2023-2025 | Opdivo, Yervoy |
| Pfizer INC. | $251.04 | 2022-2025 | |
| Gilead Sciences, INC. | $226.09 | 2022-2025 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $181.10 | 2022-2025 | Imfinzi, Enhertu, Calquence |
| Pharmaessentia USA Corporation | $157.89 | 2023-2025 | Besremi |
| Sobi, INC | $153.72 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $132.29 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Kyowa Kirin, INC. | $125.00 | 2019 | |
| Abbvie INC. | $112.20 | 2024-2025 | |
| Seagen INC. | $99.99 | 2019 | |
| Stemline Therapeutics INC. | $99.09 | 2023-2025 | Orserdu |
| Daiichi Sankyo INC. | $91.55 | 2022-2024 | Enhertu, Vanflyta |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $84.99 | 2023 | |
| Genzyme Corporation | $82.75 | 2022-2025 | |
| Janssen Biotech, INC. | $81.04 | 2024-2025 | Rybrevant, Talvey |
| Celgene Corporation | $54.22 | 2023-2024 | Reblozyl |
| Regeneron Healthcare Solutions, INC. | $53.87 | 2024 | Libtayo |
| Kite Pharma, INC. | $48.20 | 2024-2025 | Yescarta |
| Puma Biotechnology, INC. | $45.76 | 2022-2023 | Nerlynx |
| Bayer Healthcare Pharmaceuticals INC. | $39.75 | 2025 | |
| Exelixis INC. | $37.99 | 2024-2025 | Cabometyx |
| Beone Medicines USA, INC. | $32.12 | 2025 | Brukinsa, Tevimbra |
| Alexion Pharmaceuticals, INC. | $26.38 | 2024 | Ultomiris |
| Servier Pharmaceuticals LLC | $24.71 | 2025 | |
| Invivyd INC | $24.31 | 2025 | Pemgarda |
| Array Biopharma INC | $23.85 | 2025 | Braftovi, Mektovi, Xalkori |
| Immunocore Limited | $23.08 | 2025 | Kimmtrak |
| Lilly USA, LLC | $23.01 | 2024 | Verzenio |
| Karyopharm Therapeutics INC. | $22.39 | 2025 | Xpovio |
| Iovance Biotherapeutics, INC. | $22.06 | 2025 | Amtagvi |
| Eisai INC. | $19.11 | 2023 | |
| Myriad Genetic Laboratories, INC. | $18.95 | 2023 | Precisetumor |
| Sun Pharmaceutical Industries INC. | $18.69 | 2023 | Odomzo, Yonsa |
| Morphosys, US INC. | $16.56 | 2023 | Monjuvi |
| Beigene USA, INC. | $16.16 | 2023 | Brukinsa |
| Rigel Pharmaceuticals, INC. | $15.30 | 2024 | Tavalisse, Rezlidhia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.75 | 2020 | |
| Genentech USA, INC. | $13.96 | 2022 | |
| Mirati Therapeutics, INC. | $13.91 | 2023 | Krazati |
| Takeda Pharmaceuticals U.S.A., INC. | $13.86 | 2022 | |
| Sirtex Medical INC | $13.46 | 2024 | Sir-Spheres Microspheres |
| Astellas Pharma US INC | $11.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Yin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.